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Background
Amphotericin B (AmB) lipid formulations have been
introduced in antifungal therapy to reduce the toxicity of
AmB. The lipid-associated fraction of liposomal AmB
(LAMB), AmB colloidal dispersion (ABCD) and AmB
lipid complex (ABLC) exhibit different compositions,
structures, and particle sizes, which are reflected in differ-
ent plasma pharmacokinetics. Antimycotic drug concen-
trations at target-site can be essential for clinical response.
Materials and methods
Concentrations of the three therapeutically used lipid for-
mulations were determined in human body fluids and
compared to previous data from tissue samples and epi-
thelial lining fluid. AmB levels in pleural effusion of seven
patients, ascites of three patients and bile fluid obtained
from one patient were analysed after administration of a
lipid formulation. In order to calculate the penetration
ratio the concentrations in pleural effusion and bile fluid
were compared with simultaneous levels of lipid formu-
lated AmB in plasma. All samples were purified by solid
phase extraction and AmB was quantified by HPLC.
Results
Total AmB levels in pleural effusion ranged from 0.02 g/L
to 0.43 g/L. Mean levels of 0.22 ± 0.09 and 0.05 ± 0.05
were determined in ascites for the liberated and the lipid-
formulated AmB fraction, respectively. Liberated AmB
could be detected in all samples of pleural effusion (0.02
to 0.40 g/L), ascites (0.15 to 0.36 g/L) and bile fluid (0.78
g/L). Total AmB levels in pleural effusion and bile fluid
were significantly lower than the total concentrations in
plasma samples (0.40 to 6.91 g/L). Concentrations of the
lipid-associated fractions were very low in body fluids
(<0.11 g/L). AmB concentrations in pleural effusions cor-
related positively with the cumulative dose (r = 0.96, p =
0.01).
Conclusion
After treatment with lipid formulations, AmB concentra-
tions in pleural effusion and in ascites were substantially
lower in body fluids than in plasma samples and human
tissue. Long-term treatment with high doses of AmB lipid
formulations as well as additional therapeutic interven-
tions will be required for the eradication of fungal patho-
gens from body fluids.
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